These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21900400)

  • 1. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.
    Zhang C; Wang L; Wu D; Chen H; Chen Z; Thomas-Ahner JM; Zynger DL; Eeckhoute J; Yu J; Luo J; Brown M; Clinton SK; Nephew KP; Huang TH; Li W; Wang Q
    Cancer Res; 2011 Nov; 71(21):6738-6748. PubMed ID: 21900400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.
    Sunkel B; Wu D; Chen Z; Wang CM; Liu X; Ye Z; Horning AM; Liu J; Mahalingam D; Lopez-Nicora H; Lin CL; Goodfellow PJ; Clinton SK; Jin VX; Chen CL; Huang TH; Wang Q
    Nucleic Acids Res; 2016 May; 44(9):4105-22. PubMed ID: 26743006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
    Gerhardt J; Montani M; Wild P; Beer M; Huber F; Hermanns T; Müntener M; Kristiansen G
    Am J Pathol; 2012 Feb; 180(2):848-61. PubMed ID: 22138582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
    Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T
    PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
    Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.
    Gao S; Chen S; Han D; Wang Z; Li M; Han W; Besschetnova A; Liu M; Zhou F; Barrett D; Luong MP; Owiredu J; Liang Y; Ahmed M; Petricca J; Patalano S; Macoska JA; Corey E; Chen S; Balk SP; He HH; Cai C
    Nat Genet; 2020 Oct; 52(10):1011-1017. PubMed ID: 32868907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression.
    Zhao JC; Fong KW; Jin HJ; Yang YA; Kim J; Yu J
    Oncogene; 2016 Aug; 35(33):4335-44. PubMed ID: 26751772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics.
    Comstock CE; Knudsen KE
    Cell Cycle; 2007 Jun; 6(11):1307-13. PubMed ID: 17568191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.
    Decker KF; Zheng D; He Y; Bowman T; Edwards JR; Jia L
    Nucleic Acids Res; 2012 Nov; 40(21):10765-79. PubMed ID: 23019221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis.
    Sprenger CC; Vail ME; Evans K; Simurdak J; Plymate SR
    Oncogene; 2002 Jan; 21(1):140-7. PubMed ID: 11791184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
    Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
    Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.
    Han D; Chen S; Han W; Gao S; Owiredu JN; Li M; Balk SP; He HH; Cai C
    Cancer Res; 2019 Oct; 79(20):5260-5271. PubMed ID: 31444154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 16. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
    Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
    Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
    Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
    Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXA1 in prostate cancer.
    Dong HY; Ding L; Zhou TR; Yan T; Li J; Liang C
    Asian J Androl; 2023; 25(3):287-295. PubMed ID: 36018068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.